Literature DB >> 20202090

Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.

Wei Zhong Li1, Xiao Yan Wang, Zu Guo Li, Jin Hua Zhang, Yan Qing Ding.   

Abstract

BACKGROUND: Overexpression of cyclooxygenase-2 (COX-2) is associated with carcinogenesis, invasiveness, and metastasis of malignant tumors. Inhibition of COX-2 is one hot topic of research in prevention and treatment of malignant tumors. Because of the selective and specific inhibition on the activity of COX-2, the roles of celecoxib in prevention and treatment of tumors have attracted broad attention in recent years. In this study, we investigated the inhibitory effect of celecoxib combined with cisplatin on the proliferation of human tongue squamous cell carcinoma cell line Tca8113 in vivo and in vitro.
METHODS: Human tongue squamous cell carcinoma tumor cells Tca8113 and a mouse model with Tca8113 cells were used to study the growth inhibition of cisplatin enhanced by celecoxib. Drug treatment of Tca8113 in vitro and mice bearing xenografts in vivo were used. The level of COX-2 expression was detected by Western blotting. Sensitivity of cells to drug treatment was analyzed by MTT assay.
RESULTS: Treatment of Tca8113 cells with cisplatin (CDDP) had less effect on the expression of COX-2, whereas the COX-2 expression was significantly down-regulated after treatment with celecoxib alone or in combination with CDDP for 24 h. In addition, the combination of celecoxib with CDDP was also able to inhibit the Tca8113 line heterotransplanted in Balb/c nude mice.
CONCLUSIONS: Those findings indicate that a low dose of celecoxib could augment CDDP-induced growth inhibition of Tca8113 cells and its xenograft in Balb/c nude mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202090     DOI: 10.1111/j.1600-0714.2009.00885.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

1.  Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Authors:  Lucia Hiľovská; Rastislav Jendželovský; Peter Fedoročko
Journal:  Mol Clin Oncol       Date:  2014-10-16

2.  Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis.

Authors:  Bin Yang; Lin Jia; Qiaojuan Guo; Hui Ren; Yanping Hu; Tao Xie
Journal:  Oncotarget       Date:  2016-07-26

3.  Proteomic analysis of serum deprivation in tongue squamous cell carcinoma.

Authors:  Junfeng Zhang; Wei Dong; Yufen Meng; Miao Jiang; Zhen Zhan
Journal:  Mol Med Rep       Date:  2017-10-17       Impact factor: 2.952

4.  Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo.

Authors:  Zhi-Jun Dai; Xiao-Bin Ma; Hua-Feng Kang; Jie Gao; Wei-Li Min; Hai-Tao Guan; Yan Diao; Wang-Feng Lu; Xi-Jing Wang
Journal:  Cancer Cell Int       Date:  2012-12-19       Impact factor: 5.722

5.  Celecoxib suppresses lipopolysaccharide-stimulated oral squamous cell carcinoma proliferation in vitro and in vivo.

Authors:  Hisato Yoshida; Hitoshi Yoshimura; Shinpei Matsuda; Satoshi Yamamoto; Masahiro Ohmori; Keiichi Ohta; Takashi Ryoke; Hayato Itoi; Tamotsu Kiyoshima; Motohiro Kobayashi; Kazuo Sano
Journal:  Oncol Lett       Date:  2019-10-10       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.